References
- Asano H, Toyooka S, Tokumo M, et al (2006). Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res, 12, 43-8. https://doi.org/10.1158/1078-0432.CCR-05-0934
- Bai H, Wang Z, Wang Y, et al (2013). Detection and clinical significance of intratumoral egfr mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS One, 8, 54170. https://doi.org/10.1371/journal.pone.0054170
- Chang YL, Wu CT, Shih JY, et al (2011). Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol, 18, 543-50. https://doi.org/10.1245/s10434-010-1295-6
- Chen ZY, Zhong WZ, Zhang XC, et al (2012). EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. The Oncologist, 17, 978-85. https://doi.org/10.1634/theoncologist.2011-0385
- Chu H, Zhong C, Xue G, et al (2013). Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Oncol Rep, 30, 2311-5.
- Chung CH, Seeley EH, Roder H, et al (2010). Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev, 19, 358-65. https://doi.org/10.1158/1055-9965.EPI-09-0937
- Cortot AB, Italiano A, Burel-Vandenbos F, et al (2010). KRAS mutation status in primary non-small cell lung cancer and matched metastases. Cancer, 116, 2682-7. https://doi.org/10.1002/cncr.25014
- Daniele L, Cassoni P, Bacillo E, et al (2009). Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol, 4, 684-8. https://doi.org/10.1097/JTO.0b013e3181a52359
- Didelot A, Le Corre D, Luscan A, et al (2012). Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol, 92, 275-80. https://doi.org/10.1016/j.yexmp.2012.03.001
- Esterbrook G, Anathhanam S, Plant PK (2013). Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer. Lung Cancer, 80, 30-4. https://doi.org/10.1016/j.lungcan.2012.12.017
- Felip E, Stahel RA, Pavlidis N, et al (2005). ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol, 16, 28-29.
- Gao J, Chen JQ, Zhang L, et al (2012). Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system. Zhonghua Bing Li Xue Za Zhi, 41, 652-6.
- Han CB, Ma JT, Li F, et al (2012). EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. Cancer Letters, 314, 63-72. https://doi.org/10.1016/j.canlet.2011.09.012
- Hansen HH (2002). Treatment of advanced non-small cell lung cancer. BMJ, 325, 452-3. https://doi.org/10.1136/bmj.325.7362.452
- Hironobu O Takashi A, Motohiko K, et al (2012). Comparison of epidermal growth factor receptor mutation analysis results between surgically resected primary lung cancer and metastatic lymph nodes obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Thoracic Cancer, 3, 262-8. https://doi.org/10.1111/j.1759-7714.2012.00122.x
- Ho HL, Chang FP, Ma HH, et al (2013). Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: Comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirology, 18, 1261-70. https://doi.org/10.1111/resp.12148
- Hu YC, Zhang Q, Huang YH, et al (2014). Comparison of two methods to extract dna from formalin- fixed, paraffin-embedded tissues and their impact on EGFR mutation detection in non-small cell lung carcinoma. Asian Pac J Cancer Prev, 15, 2733-7. https://doi.org/10.7314/APJCP.2014.15.6.2733
- Hung MS, Lin CK, Leu SW, et al (2006). Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J, 29, 373-9.
- Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
- Jing CW, Wang Z, Cao HX, et al (2013). High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixedparaffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 6619-23. https://doi.org/10.7314/APJCP.2013.14.11.6619
- Katsuhiko S, Takuro Y, Yuji H, et al (2013). Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Target Oncol, 8, 237-42. https://doi.org/10.1007/s11523-012-0241-x
- Kidd EA, Grigsby PW (2008). Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res, 14, 5236-41. https://doi.org/10.1158/1078-0432.CCR-07-5252
- Matsumoto S, Takahashi K, Iwakawa R, et al (2006). Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer, 119, 1491-4. https://doi.org/10.1002/ijc.21940
- Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. https://doi.org/10.1056/NEJMoa0810699
- Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc, 83, 584-94. https://doi.org/10.1016/S0025-6196(11)60735-0
- Morita S, Okamoto I, Kobayashi K, et al (2009). Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res, 15, 4493-8. https://doi.org/10.1158/1078-0432.CCR-09-0391
- Nagai Y, Miyazawa H, Huqun, et al (2005). Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res, 65, 7276-82. https://doi.org/10.1158/0008-5472.CAN-05-0331
- Nakano H, Soda H, Takasu M, et al (2008). Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer, 60, 136-40. https://doi.org/10.1016/j.lungcan.2007.08.021
- Neal N, James MB, Matthew N, et al (2012). Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med, 185, 1316-22. https://doi.org/10.1164/rccm.201202-0294OC
- Pao W, Ladanyi M (2007). Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res, 13, 4954-5. https://doi.org/10.1158/1078-0432.CCR-07-1387
- Park S, Holmes-Tisch AJ, Cho EY, et al (2009). Discor-dance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol, 4, 809-15. https://doi.org/10.1097/JTO.0b013e3181a94af4
- Qin F, Hua Y, Wei O, et al (2012). Discordance of epidermal growth factor receptor mutations between primary tumors and corresponding mediastinal nodal metastases in patients operated on for stage N2 non-small cell lung cancer. Thoracic Cancer, 3, 313-9. https://doi.org/10.1111/j.1759-7714.2012.00163.x
- Sakurada A, Lara-Guerra H, Liu N, et al (2008). Tissue heterogeneity of EGFR mutation in lung adenocarcinoma.J Thorac Oncol, 3, 527-9. https://doi.org/10.1097/JTO.0b013e318168be93
- Sasaki H, Yukiue H, Mizuno K, et al (2003). Elevated serum epidermal growth factor receptor level is correlated withlymph node metastasis in lung cancer. Int J Clin Oncol, 8, 79-82. https://doi.org/10.1007/s101470300014
- Schmid K, Oehl N, Wrba F, et al (2009). EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res, 15, 4554-60. https://doi.org/10.1158/1078-0432.CCR-09-0089
- Sequist LV, Waltman BA, Dias-Santagata D, et al (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 75.
- Shih JY, Gow CH, Yu CJ, et al (2006). Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer, 118, 963-9. https://doi.org/10.1002/ijc.21458
- Silvestri GA, Gould MK, Margolis ML, et al (2007). Noninvasive staging of non-small cell lung cancer:ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 132, 178-201. https://doi.org/10.1378/chest.07-0554
- Sun L, Zhang Q, Luan H , et al (2011). Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res, 30, 79-82. https://doi.org/10.1186/1756-9966-30-79
- Wang T, Nelson RA, Bogardus A, et al (2010). Five-year lung cancer survival: which advanced stage non-small cell lung cancer patients attain long-term survival? Cancer, 16, 1518-25.
- Wang X, Ramaswamy V, Remke M, et al (2013). Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. Neurosurgery, 60, 57-63. https://doi.org/10.1227/01.neu.0000430318.01821.6f
- Yatabe Y, Matsuo K, Mitsudomi T, et al (2011). Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol, 29, 2972-7. https://doi.org/10.1200/JCO.2010.33.3906
Cited by
- High Feasibility of Liquid-Based Cytological Samples for Detection of EGFR Mutations in Chinese Patients with NSCLC vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7885
- Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review vol.34, pp.1, 2015, https://doi.org/10.1186/s13046-015-0207-9
- Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer vol.11, pp.9, 2016, https://doi.org/10.1371/journal.pone.0163652
- Targeted Therapy Management in NSCLC Patients Using Cytology: Experience from a Tertiary Care Cancer Center vol.20, pp.2, 2016, https://doi.org/10.1007/s40291-015-0180-1